

comprising from about 2% to about 75% by weight of *d-threo*-methylphenidate in admixture with one or more binders, and a coating consisting of an ammonio methacrylate copolymer in an amount sufficient to provide a dose of said *d-threo*-methylphenidate hydrochloride delayed by from about [4] 2 hours to about 7 hours following said ingestion.

2 Add new claims 4 <sup>13</sup> as follows:

A method for treating disease amenable to treatment with a phenidate drug in a patient in need of such treatment comprising administering to the patient a dosage form providing once-daily oral administration of the phenidate drug, said dosage form comprising two groups of particles, each containing the drug wherein:

a) said first group of particles comprises from about 2% to about 99% by weight of the phenidate drug and provides a substantially immediate dose of said phenidate drug upon ingestion by a mammal; and

b) said second group of particles comprises coated particles, said coated particles comprising from about 2% to about 75% by weight of the phenidate drug in admixture with one or more binders, and a coating consisting of an ammonio methacrylate copolymer in an amount sufficient to provide a dose of said phenidate drug delayed by from about 2 hours to about 7 hours following said ingestion.

The method of claim <sup>3</sup> 4 wherein said delay is at least about 3 hours.

The method of claim <sup>3</sup> 4 wherein said delay is at least about 4 hours.

The method of claim 1 wherein said delay is at least about 3 hours.

The method of claim 1 wherein said delay is at least about 4 hours.

The dosage form of claim 2 wherein the temporal separation is at least about 3 hours.

The dosage form of claim 2 wherein the temporal separation is at least about 4 hours.

The dosage form of claim <sup>2</sup> 3 wherein the temporal separation is at least about 3 hours.

The dosage form of claim <sup>2</sup> 3 wherein the temporal separation is at least about 4 hours.